TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05758727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The exercise programme is progressive and has three levels. Each bout of exercise and Tai-chi snacking consists of 5 exercises. Each exercise is performed for one minute with one minute rest in between. For exercise snacking movements (including leg exercise, shoulder exercise, single leg exercise, arm exercise, and ankle exercise), participants are encouraged to complete as many repetitions as possible of that exercise in that minute. For Tai-chi snacking movements (including single leg squat, trunk rotation, single leg stand, hip and knee exercise, and ankle mobility exercise), participants are encouraged to complete repetitions of each exercise at a self-selected pace that is comfortable for them to maintain for the full minute, with the aim being to complete the movements as accurately and smoothly as possible (based on correct posture and proper alignment).
Study: NCT04986683

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain magnetic resonance imaging
Description: Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate the presence, type, and severity of brain abnormalities in enrolled subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-psychology testing
Description: Participants will undergo age-appropriate neuro-psychology testing to assess motor, language, and other neurocognitive functions potentially affected by drug-resistant epilepsy.
Study: NCT06194734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
Study: NCT06061783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotonic Solution
Description: Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water Purified
Description: administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
Study: NCT04840992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo
Study: NCT06021353

Intervention type: DEVICE
Group type: OTHER
Intervention: IR fs-Laser
Description: Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LASIK
Description: Laser-assisted in situ keratomileusis (LASIK) surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LASIK
Description: Laser-assisted in situ keratomileusis (LASIK) surgery
Study: NCT04997902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral administration
Study: NCT06301087

Intervention type: DEVICE
Intervention: Web Application
Description: web application for monitoring children's development and postnatal depression of mothers
Study: NCT05506878

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NSS-2 BRIDGE
Description: NBD® will be applied to either the right or left ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.~Once the device is placed, subjects will be asked to perform a pinch test throughout the duration of their time wearing the device. To perform the pinch test subjects must pinch down on the electrodes and ground to ensure the electrodes are still placed in their designated locations and have not come loose.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NSS-2 BRIDGE
Description: Sham NBD® will be applied to either the left or right ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.
Study: NCT04997902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Oral administration
Study: NCT05489406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG DT (6 x 5 mg)
Description: DTG 5mg dispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG DT (6 x 5 mg)
Description: DTG 5mg dispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF TOS (3 x 60/7.5 mg)
Description: 60/7.5 mg TOS emtricitabine/TAF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF TOS (3 x 60/7.5 mg)
Description: 60/7.5 mg TOS emtricitabine/TAF
Study: NCT04018508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
Study: NCT05340244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational ultrasound exam
Description: Eligible subjects will be enrolled into the study and positioned for their ultrasound exam. Standard clinical practice procedures will be followed using the standard of care device at the site to complete the clinically indicated exams.~After the clinically indicated exam, portions of the TTE and/or TEE exam will be repeated with the investigational ultrasound device.
Study: NCT06346769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene Fiber
Description: In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene Fiber
Description: In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene Fiber
Description: In the restoration of the endodontically treated posterior teeth, polyethylene fiber was placed in different directions ('O' shape, mesiodistal I shape, buccolingual I shape) according to the amount of remaining tooth tissue and cavity preparation.
Study: NCT04840992

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Inhalation
Description: Aerogen Solo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study: NCT05277649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Performing a programme of warm-up and stretching exercises for the cervico-mandibular region aimed at improving mobility and muscle condition.
Study: NCT04852406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protocol-based management of perioperative antithrombotic therapy
Description: Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Routine management of perioperative antithrombotic therapy
Description: Perioperative antithrombotic therapy is managed according to current routine practice.
Study: NCT05120999

Intervention type: DEVICE
Intervention: Train of four measurement
Description: Use of either TetraGraph or TOFScan to measure the neuromuscular blockade

Intervention type: DEVICE
Intervention: Train of four measurement
Description: Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
Study: NCT05476185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READY4Life Programming - classroom instruction
Description: The intervention group receives 16 hours of classroom instruction.
Study: NCT04875338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plate-rich plasma
Description: 1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline (0.9 NACI)
Description: 1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betametazon
Description: 1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
Study: NCT04460612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active IR sock
Description: Subjects will be wearing the infrared socks for 60 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active IR sock
Description: Subjects will be wearing the infrared socks for 60 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo socks
Description: Placebo Socks will be placed on participants feet first for 60 minute

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo socks
Description: Placebo Socks will be placed on participants feet first for 60 minute
Study: NCT05300919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement based care
Description: Measurement-based care based on arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement based care
Description: Measurement-based care based on arm.
Study: NCT05847842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior quadratus lumborum block
Description: 20 mL of 0.25% bupivacaine will be given

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: 20 mL of 0.25% bupivacaine will be given

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: 20 mL of 0.25% bupivacaine will be given
Study: NCT05244018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 tablets
Description: Vitamin D3 tablets 50,000 IU units
Study: NCT04645069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG126 Mono
Description: ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG126 Mono
Description: ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG126-anti PD1
Description: ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG126-anti PD1
Description: ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG126-ADG106
Description: ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG126-ADG106
Description: ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
Study: NCT06249295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral cryotherapy
Description: The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth)
Study: NCT05974644

Intervention type: OTHER
Intervention: Registry
Description: The purpose of this registry is to collect and store health information from people who are carriers of the gene known to cause hereditary amyloidosis and those with a confirmed diagnosis of the disease.

Intervention type: OTHER
Intervention: Registry
Description: The purpose of this registry is to collect and store health information from people who are carriers of the gene known to cause hereditary amyloidosis and those with a confirmed diagnosis of the disease.
Study: NCT05206630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED Physical Therapy
Description: All ED Physical Therapy treatment classifications involve a combination of exercise, range of motion, education, prognostic guidance, and reassurance. Patients are provided with an individualized home exercise plan based on their matched treatment classification and/or active rest.
Study: NCT06466564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nufairy® Coil embolization system for intracranial aneurysm
Description: Nufairy® Coil embolization system for intracranial aneurysm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nufairy® Coil embolization system for intracranial aneurysm
Description: Nufairy® Coil embolization system for intracranial aneurysm
Study: NCT06234644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Walking Obstacle Course (SWOC)
Description: The Standardized Walking Obstacle Course (SWOC) is a test that allows interaction of a child with environmental demands and obstructions while examining differences in functional ambulation performances. The Group A (experimental group) will receive the treatment with Standardized walking obstacle course (SWOC), the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of SWOC training and 5 minutes of cool down period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Training
Description: Conventional gait training protocol including walking on a treadmill, parallel bar walk, seated marching. The Group B (Control group) will receive the treatment with conventional Gait training, the group of 13 participants will receive the treatment. This group will receive therapy session for 45 min, thrice a week for 6 weeks, total sessions will be 18. 45 minutes session time will be divided into 15 min warm up period, 25 minutes of Conventional gait training and 5 minutes of cool down period.
Study: NCT04998318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket Colposcope
Description: Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Colposcopy
Description: VIA and VILI as previously described,
Study: NCT06343896

Intervention type: OTHER
Intervention: monitorization reliability
Description: evaluation of the use of the integral pulmonary index in the child patient group
Study: NCT05974085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor+RCHOP
Description: XPO-1 inhibitor selinexor in combination with RCHOP
Study: NCT05244018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D tablets
Description: Vitamin D tablets 5000 units as daily requirements
Study: NCT05642013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early prosthesis reimplantation
Description: Early prosthesis reimplantation, within 16 to 30 days after implants removal

Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective analysis of medical records
Description: Analysis of 50 records of operated patients managed with classical two-stage implant exchange
Study: NCT06279130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botensilimab
Description: Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balstilimab
Description: Anti programmed cell death protein-1 (anti-PD1)
Study: NCT05844631

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Release
Description: One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
Study: NCT06575296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT04641247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib tablets or capsules will be given once a day via the oral route.